Quarterly report
Open the filing on sec.gov
Savara Inc. (SVRA)
Nasdaq: SVRA · Pharmaceutical Preparations · Austin, TX · filing with the SEC since 2001
The companyfiscal 2020, as filed
Revenue$257,000
Net income-$49.6M+36.5%
Earnings per sharen/a
Operating cash flow-$39.8M+11.7%
Cash$22.9M-54.1%
Debt$25.1M
Shareholders’ equity$64.4M-36.7%
Shares, dilutedn/a
Return on equity-58.5%
The recordfrom its filings
Filings in 202625
Newest filingNov 9 · 10-Q
Annual reportMar 13, 2026
Quarterly reportNov 9, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$2.4M
Insider buys, 12 months$0.00
Patents granted13
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$153MCash from operations -$130Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Annual report to shareholders
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.